References
- Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009 Nov;60(11):1439–1445.
- McIntyre RS. A vision for drug discovery and development: novel targets and multilateral partnerships. Adv Ther. 2014 Mar;31(3):245–246.
- McEwen BS. Mood disorders and allostatic load. Biol Psychiatry. 2003 Aug 1;54(3):200–207.
- Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010 Jul;167(7):748–751.
- Serafini G, Hayley S, Pompili M, et al. Hippocampal neurogenesis, neurotrophic factors and depression: possible therapeutic targets? CNS Neurol Disord Drug Targets. 2014;13(10):1708–1721.
- Fava M, Johe K, Ereshefsky L, et al. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 Oct;21(10):1372–1380.
- Johe K, Marquez A, Anaya C, et al. Therapeutic efficacy of NSI-189 in diabetic mice. Neuralstem, Inc; Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (European Association for the Study of Diabetes), held in Bucharest, Romania. 2016.
- Liu Y, Hefferan MP, Johe K, et al. NSI-189, a neurogenic compound enhances short-term and long-term potentiation in C57BL/6 mice and reverses LTP impairment in a mouse model of Angelman Syndrome. Pomona, CA 91766, Germantown, MD 20876: Western University of Health Sciences and Neuralstem, Inc.; 2016.
- Allen BD, Archarya MM, Lu C, et al. Reversal of radiation-induced cognitive impairment by oral administration of neurogenic small molecule compound NSI-189. Radiation Research Society Annual Meeting, October 19, 2017. 2017.
- Tajiri N, Quach DM, Kaneko Y, et al. NSI-189, a small molecule with neurogenic properties, exerts behavioural and neurostructural benefits in stroke rats. J Cell Physiol. 2017 Feb 9. doi: 10.1002/jcp.25847